• 4D Molecular Therapeutics President and CEO David Kirn sold 58,333 common shares on July 9-10.
• Sales were reported at weighted-average prices of USD 12.87, USD 12.01, USD 12.84.
• Kirn held 884,152 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001834021-26-000004), on July 14, 2026, and is solely responsible for the information contained therein.